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Abstract
Resistance to xenobiotics remains a pressing issue in parasite treatment and glo-
bal agriculture. Multiple factors may affect the evolution of resistance, including
interactions between life-history traits and the strength of selection imposed by
different drug doses. We experimentally created replicate selection lines of free-
living Caenorhabditis remanei exposed to Ivermectin at high and low doses to
assess whether survivorship of lines selected in drug-treated environments
increased, and if this varied with dose. Additionally, we maintained lines where
mortality was imposed randomly to control for differences in density between
drug treatments and to distinguish between the evolutionary consequences of
drug-treatment versus ecological processes due to changes in density-dependent
feedback. After 10 generations, we exposed all of the selected lines to high-dose,
low-dose and drug-free environments to evaluate evolutionary changes in sur-
vivorship as well as any costs to adaptation. Both adult and juvenile survival were
measured to explore relationships between life-history stage, selection regime and
survival. Intriguingly, both drug-selected and random-mortality lines showed an
increase in survivorship when challenged with Ivermectin; the magnitude of this
increase varied with the intensity of selection and life-history stage. Our results
suggest that interactions between density-dependent processes and life history
may mediate evolved changes in susceptibility to control measures.
Introduction
Pesticide and drug treatments are designed to suppress
populations of parasites, pests and disease vectors. This
makes them strong selective factors; as a result, adaptation
consistently occurs in natural populations exposed to xeno-
biotics (Jackson 1993; Carriere et al. 1994; Wolstenholme
et al. 2004; Sparks et al. 2012). Resistance can evolve
quickly (Lopes et al. 2008; Brausch and Smith 2009;
Tabashnik et al. 2014), and the development of resistance
is becoming an important theme in applied evolutionary
biology due to the risk of reduced efficacy of chemical
applications to control parasite and pest species (Palumbi
and Mu 2001; REX Consortium 2010, 2013; Hendry et al.
2011). However, evolutionary strategies which could curtail
the rate of resistance evolution have yet to be adopted uni-
versally (Greene et al. 2012). Several factors are known to
affect the rate at which parasites can evolve resistance,
including the type of drug, dosage, timing of application,
migration rates between susceptible and resistant popula-
tions, the standing frequency of resistance alleles in the
population and the specific mechanisms of resistance
(Committee on Strategies for the Management of Pesticide
Resistant Pest Populations 1986; Barnes et al. 1995; Gil-
leard and Beech 2007; James et al. 2009; REX Consortium
2013). Low population densities in drug-treated environ-
ments may also have some influence on susceptibility if
there are interactions between susceptibility and competi-
tion for resources or any other density-dependent pro-
cesses. However, it is difficult to tease apart the effects of
mortality caused by the drug from those caused by density-
dependence (Gilleard and Beech 2007). In addition, life-
history characteristics and reproductive strategies of
parasites and pests could influence the rate at which resis-
tance develops (Galvani and Gupta 1998; Lynch et al. 2008;
Kliot and Ghanim 2012). The influence of such factors, and
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their interactions, on resistance evolution has been consid-
ered theoretically but there has been little attempt to show
that these factors are of practical significance in the labora-
tory or field.
Experimentation and monitoring of complicated host–
parasite systems is technically difficult, expensive and time-
consuming (Leathwick et al. 2009) and thus resistance
evolution is often predicted by simulations. For example,
Barnes et al. (1995) used mathematical modeling to inves-
tigate the effects of under-dosing on the evolution of resis-
tance. They suggested that the outcome of under-dosing in
terms of the rate of resistance evolution would depend on
the genetic mechanism underlying resistance. An alterna-
tive to allow specific testing of factors associated with resis-
tance while maintaining more biological complexity, is to
use laboratory models to simulate the evolutionary process
(Taylor et al. 1983; Lopes et al. 2008; Busi and Powles
2009). Previous experimental evolution studies have
reported rapid evolution of drug resistance in a variety of
organisms; including insects, nematodes, and other inverte-
brates (Barros et al. 2001; Lopes et al. 2008; Jansen et al.
2011). These studies often employ one of two strategies in
generating resistance: (i) impose a continuous drug or pes-
ticide dose on a population and monitor adaptation over a
number of generations; or (ii) increase drug dose at regular
intervals, often every generation, to track the dose of drug
required to cause a target mortality level (e.g. 50% mortal-
ity; LD50) in the population under selection. Few studies
have specifically looked at the effect of dosage on the rate
of resistance evolution, although Busi and Powles (2009)
found that selection under exposure to both low and high
doses of glyphosate caused a rapid increase in survival of
rye grass over three generations and that higher doses pro-
moted a greater magnitude of resistance. However, resis-
tance screens were performed on the first generation
offspring of selected plants, therefore any response could
have been due to maternal effects. Experimental selection
over multiple generations at different sublethal doses would
help to further elucidate the relationship between dose and
the rate of resistance evolution.
In addition to dosage, differences in population density
between treated lines of parasites and pests could result in
differential selection due to density-dependent processes
such as competition (Gilleard and Beech 2007). Labora-
tory-based selection experiments often impose strong selec-
tion on generation time or timing of reproduction when
reproductive strategies are influenced by density-dependent
effects (Chehresa et al. 1997). Since the application of a
drug or pesticide treatment reduces population size, this
will create differences in population density between treat-
ments, which could alter the apparent evolution of resis-
tance due to changes in traits that are not directly
associated with responding to chemical exposure (Gilleard
and Beech 2007). Selection experiments investigating the
rate of resistance evolution typically involve comparisons
of survival and/or life history in a drug treatment com-
pared to a control treatment with no drug applied (Ranjan
et al. 2002; Coles et al. 2005; Lopes et al. 2008). However,
this methodology does not account for differences in popu-
lation density resulting from differences in mortality
between the treatments. If studies are to be biologically
realistic and drug treatments involve the bottlenecking of
populations, then the experimental design must separate
the indirect effects of reduced density from the direct
effects of the drug (Fuller et al. 2005).
The treatment of helminth diseases provides a well-docu-
mented field of research in which to explore problems
related to resistance evolution using an experimental
approach (Driscoll 1989; Sangster and Gill 1999; Kaplan
and Vidyashankar 2011). Ivermectin is a broad-spectrum
antiparasitic drug and has been used commercially since
1981 (James et al. 2009), with the first reports of resistance
in 1988 (Kaplan 2004). Ivermectin causes paralysis in larvae
and adult nematodes and inhibits feeding (Sangster and
Gill 1999), but also has a repellent effect at sublethal doses
(Ardelli et al. 2009). Because parasitic helminths are diffi-
cult to culture, research into anthelmintic resistance has a
long history of using the model organism Caenorhabditis
elegans in both drug screening and identifying candidate
resistance loci (Simpkin and Coles 1981; James et al. 2009;
Ghosh et al. 2012). However, C. elegans is an androdioe-
cious nematode species that reproduces mainly by self-fer-
tilization, although low levels of outcrossing do occur as a
result of the small proportion of males present in a popula-
tion (Brenner 1974; Barriere and Felix 2007). Since most
parasitic nematodes are dioecious and obligately outcross-
ing, other free-living dioecious nematodes such as
Caenorhabditis remanei may provide a more realistic model
system to explore resistance evolution. Caenorhabditis
remanei populations have abundant standing genetic varia-
tion and high levels of recombination due to their reliance
on sexual reproduction (Cutter et al. 2006). Both of these
attributes should facilitate a rapid response to selection.
Additionally, Caenorhabditis species provide an effective
microcosm system, which has been used to answer a broad
range of evolutionary questions related to rapid evolution-
ary change (Lopes et al. 2008; Morran et al. 2011; Gray
and Cutter 2014). Manipulating drug dosage, as well as
controlling for differences in population density between
treated lines in simple microcosm systems, may provide us
with a better understanding of how natural populations of
parasites and pests adapt to control measures.
The terms resistance and tolerance are often used inter-
changeably when defining reduced susceptibility to xenobi-
otics and has led to much confusion on their relative
importance in the evolution of reduced susceptibility.
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Tabashnik et al. (2014) define resistance as a genetically
based decrease in susceptibility as a result of exposure to a
control agent; this definition emphasizes a heritable change
in susceptibility of a target population due to previous
exposure to a control measure. In other words, the spread
of resistance through a population is the result of an
increase in frequency of pre-existing alleles conferring
reduced susceptibility, novel or spontaneous mutations or
migration of resistance alleles between populations during
a period of time where the population is exposed to a drug
(Gilleard and Beech 2007). By this definition, a population
cannot be resistant prior to exposure to a control agent and
resistance results as an evolved response, specifically due to
drug application. Tolerance, on the other hand, is due to
natural variation in susceptibility already pre-existing
within or between populations rather than a result of selec-
tion pressure imposed by control measures (Scott 1995).
Tolerance may also be used to describe pre-existing differ-
ences in susceptibility between different species or between
life-history stages of organisms (Coles and Dryden 2014).
For example, sensitivity to Ivermectin has been shown to
vary substantially among species of sepsid dung flies (Puni-
amoorthy et al. 2014). Puniamoorthy et al. (2014) found
that tolerance was explained by phylogenetic relationships;
more closely related species had similar levels of suscepti-
bility to Ivermectin on naive exposure. However, they
could not rule out the possibility of rapid adaptation of
species to Ivermectin but suggested that this was unlikely as
they found more variation in Ivermectin sensitivity
between species within sample sites than variation within
species between sample sites. Additionally, some of the least
susceptible species were known to be drug naive as they
were sampled from locations where anthelmintics have not
been used. This suggests that tolerance may occur due to
pleiotropic effects and selection on some other unknown
trait may result in pre-adaptation in the form of reduced
susceptibility. If the frequency and magnitude of tolerance
within a population is affected by selection on unknown
traits, the factors which effect selection on those traits will
play an important role in governing susceptibility to con-
trol agents prior to exposure. In addition, drug-treated
populations could evolve tolerance in parallel to resistance
if evolved decreases in susceptibility are associated with
density-dependent selection, and affect the apparent rate of
resistance evolution (Gilleard and Beech 2007). It is diffi-
cult to separate tolerance from resistance unless this is
explicitly incorporated into the experimental design but
this also requires knowledge about which traits confer dif-
ferences in tolerance to a particular xenobiotic.
The overall aim of this study was to assess how Iver-
mectin dosage, and changes in population density affect
the rate of resistance evolution in replicate lines of C. re-
manei. Specifically, we asked: (i) What is the relationship
between C. remanei survival and Ivermectin dose over a
range of concentrations within a single generation? (ii) Is
there an increase in survivorship across generations of pop-
ulations selected in drug-treated environments, and does
this vary with dosage? (iii) Does density-dependent selec-
tion affect the apparent evolution of resistance in selected
lines? (iv) Is there a cost of adaptation to drug-treated envi-
ronments in terms of survival in drug-free environments?
We also explored the relationship between life-history
and drug selection, asking: (v) Does survival of different
life-history stages (juvenile and adult) respond to drug-
selection in the same way?
Methods
Origin and maintenance of experimental lines
In order to maximize the degree of standing genetic
variation available to select for resistance, we obtained a
genetically diverse strain of C. remanei (SP8) from N. Tim-
mermeyer in the Department of Biology, University of
T€ubingen, Germany. This strain was originally created by a
fully factorial crossing of three wild-type strains isolated
from geographically distant locations (SP146 from Frei-
burg, Germany; MY31 from T€ubingen, Germany; PB206
Ohio, USA). Crosses had been tested for fertility, offspring
pooled, and maintained for eight generations to create
recombinant genotypes and allow adaptation to standard
laboratory conditions (Fritzsche et al. 2014). Upon arrival
in Glasgow, strain SP8 spent a further four generations
adapting to any differences in conditions between laborato-
ries and was maintained under standard laboratory condi-
tions for Caenorhabditis species: 20°C and 60% humidity
on NGM (Nematode growth medium) petri dishes and fed
on a lawn of Escherichia coli (OP50) (Hope 2001).
Dose–response assay
In order to choose two distinct doses that differ in the
intensity of selection imposed during the selection experi-
ment, it was first necessary to quantify the relationship
between drug dosage and survivorship for strain SP8. A
stock solution of 2 mg/mL Ivermectin (22,23-Dihydroaver-
mectin B1; Sigma-Aldrich) dissolved in DMSO was dec-
anted into 1 mL aliquots and frozen to provide a
standardized drug dose. We used a modified version of the
dose–response approach taken by Rufener et al. (2010) to
quantify survivorship of C. remanei over a range of doses
(0, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 10 ng/mL).
Appropriate dilutions of Ivermectin were administered to
100 mL liquid NGM (50°C) and mixed with a magnetic
stirrer before pouring 7 mL aliquots into 5.5 cm plastic
petri dishes. These were left to dry, seeded with E. coli
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(OP50) ad libitum to minimize indirect mortality resulting
from repellence at low doses and incubated at 20°C over-
night. Concurrently to preparing dosed plates, age-syn-
chronized eggs were harvested from stock populations of
C. remanei by bleaching using standard protocols. This
process kills adults and juveniles but leaves developing
embryos unharmed (Hope 2001). Eggs were moved to fresh
9 cm drug and food-free petri dishes and incubated over-
night to provide a source of L1-arrested larvae for drug
screening. After 12 h incubation, larvae were suspended in
M9 buffer solution (3 g KH2PO4, 6 g Na2HPO4, 5 g NaCl,
1 mL 1 M MgSO4, H2O to 1 L and sterilized by autoclav-
ing) and 5 lL aliquots of this suspension were added to
Ivermectin-dosed plates with the aim of applying approxi-
mately 60 larvae per plate. Larvae added to petri dishes
were counted as they were set-up; survival data were
obtained by counting the number of adults present per
plate at 75 h. Caenorhabditis remanei become reproduc-
tively active 2 days after hatching (Diaz et al. 2008) so sur-
vivorship was measured at 75 h after L1 larvae were
exposed to the relevant dose of Ivermectin. Twenty repli-
cate plates were established for each Ivermectin dose (ten
replicates in each of two different batches conducted at
different times).
Selection experiment
Two Ivermectin doses were chosen as drug treatments for
experimental evolution (Figure S1B): (i) a high dose that
corresponded to 80% mortality at 75 h in naive popula-
tions; and (ii) a low dose that corresponded to 40% mortal-
ity. These two doses were combined with a control of no
drug application (zero = Z, low drug = LD, and high
drug = HD, Fig. 1A). In addition, a random-mortality
treatment was included for the low and high dosages to
account for differences in density between drug treatments
(low random = LR, and high random = HR) by randomly
removing the same number of individuals from these plates
as had died in response to the corresponding drug treat-
ment. For instance, if two females and six males had died
in a drug-treated line, a sister random-mortality line had
the same number of each sex removed. All lines were
exposed to high (HD and HR) and low mortality environ-
ments (LD and LR), with three replicates per experimental
line per treatment, with the exception of the controls,
which were replicated six times.
Experimental lines were cultured for 10 generations. The
ancestral stock strain (generation 0) as well as samples of
larval worms from each line at generations 5 and 10 were
cryogenically frozen at 80°C Fig. 1A), at a density of
approximately 2000 L1 larvae in liquid freezing solution as
described in Hope (2001). Generation 1 (18 lines overall)
was initiated using standard bleaching methods from the
ancestral stock strain of SP8 cultured in the lab for four
generations after thawing and represents the ancestral con-
dition (generation 0; Fig. 1B). L1-arrested larvae were sus-
pended in M9 buffer and worm density of the suspension
obtained by counting worms from five replicates of 5-lL
aliquots. A volume of the suspension corresponding to 400
L1-larvae was then added to E. coli seeded NGM plates
(9 cm) with the appropriate dose of Ivermectin. Establish-
ing populations with 400 larvae prevented density-depen-
dent competition but still contains sufficient numbers of
individuals to ensue a substantial proportion of standing
genetic variation (Allendorf 1986). After 48 h of develop-
ment worms reach the 4th larval stage (L4) at which point
Generation 1 
2 days 
exposure Adults counted 
400 larvae Generations 2 to 10 
50 adults 
Day 1 Day 2 Day 3 
Adults counted 
Starting population of SP8 
Adapted to laboratory conditions for 12 generations 
10 generations of evolution 
Freezing and thawing: three generations
without treatment 
Resistance bioassays: SP8 ancestral strain and evolved
lines challenged with high, low and zero drug doses  
LD HR LR 
Ancestral population of SP8 randomly split into three
treatments for selection 
HD Z 
(A)
(B)
Figure 1 (A) Schematic representation of dose–response assay, selec-
tion experiment, and resistance bioassay. The starting population of
SP8 was adapted to laboratory conditions. The laboratory-adapted
strain was then assayed for variation in susceptibility to Ivermectin over
a range of 15 doses, to select an appropriate high and low dose for the
selection experiment. The laboratory-adapted strain was then randomly
divided into five treatments with three replicates each for HD, LD, HR,
and LR lines, and six replicates for Z lines. After 10 generations of selec-
tion, lines were frozen and later thawed, before being challenged with
the three doses of Ivermectin used during the original selection experi-
ments. (B) Schematic representation of selection experiment showing
initial population set-up and one generation. Initially, lines were estab-
lished with 400 larvae exposed to the relevant dose of Ivermectin; 50
adults were then selected to begin generation 1 on day 1. After 24 h
lines were counted and compensatory mortality imposed on random
lines; this was at 48 h. After 72 h, subadults from the next generation
were transferred to new plates. Generations 2–10 proceeded as for
generation 1. HD, high-dose treatment; HR, high-random treatment;
LD, low-dose treatment; LR, low-random treatment; Z, zero dose
treatment.
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the sex can be determined. At this time, 25 pairs of male
and female L4 larvae were transferred to fresh agar plates of
the appropriate dose for each replicate. These 50 adults
constituted generation 1, day 1. After 24 h, adults were
counted and census data were used to impose an equivalent
mortality on the random-mortality lines for the respective
treatments. After 48 h of drug exposure, the same process
of adult census and compensatory-induced mortality was
repeated. By 72 h, larvae from the next generation had
developed to L4 larvae: 25 pairs were selected to continue
the next generation and transferred to fresh petri dishes.
This was continued for 10 generations. Census data were
gathered each generation to assess whether there was an
increase in survivorship of lines selected in drug-treated
environments and whether this increase varied with dosage.
In addition to adult census, a juvenile census was per-
formed after 48 h to provide an estimate of juvenile popu-
lation densities. L2 and L3 larval stages were counted along
a 1 cm transect covering the center of the petri dish; L1
juveniles were too small and numerous to gather reliable
counts.
Drug-resistance bioassays
In order to formally assess whether heritable increases in
survivorship were imposed by selection with Ivermectin,
ancestral stocks (generation 0) as well as each of the
selected lines from generation 5 and 10 were exposed to the
same high and low doses of Ivermectin used during selec-
tion and raised in a drug-free environment. Firstly, to test
the effects of drug dosage on survival, revived samples of
HD, and LD lines were exposed to a dose of Ivermectin
corresponding to that used during selection. Survival of
these lines was then contrasted with survival of Z lines to
assess whether there was a change in evolved lines. Sec-
ondly, to test for effects of differences in population density
on survival of selected lines, we exposed HR and LR lines
to a high and low dose of Ivermectin, respectively. Survival
of HR and LR lines were contrasted with Z lines, with any
significant differences in survival between random mortal-
ity and Z lines indicating an effect of population density on
relative survival. Thirdly, we tested for any cost to adapta-
tion to selection regime in terms of survival by raising
evolved lines in a drug-free environment, with the hypothe-
sis that if there is a cost to adaptation, then experimentally
treated lines should show significantly lower survival than
control (Z) lines.
Preserved samples of lines from the selection experiment
at generations 0, 5, and 10 were thawed and raised for three
generations in a drug-free environment to ensure that any
observed responses in survival were due to genetic differ-
ences among populations and not maternal or environ-
mental effects due to freezing. Larvae were thawed at room
temperature and maintained at a density of approximately
1000 individuals per 9 cm agar plate over the three genera-
tions from thawing to age synchronization with ad libitum
lawns of E. coli OP50. Transfers between generations were
achieved by cutting out sufficient agar from plates already
containing samples and transferring these to fresh E. coli
seeded plates ensuring the density remained as constant as
possible. Agar plates, synchronization of experimental lines
and set-up of larvae were conducted with the same proto-
col used in the dose–response assay. Mortality due to drug
application may differ between life-history stages; in order
to gain some measure of this difference, we measured sur-
vival both at 52 h, encompassing juvenile development and
75 h, during the first day of reproduction. Generations 5
and 10 of each experimental line were replicated four times,
as was the ancestral line (generation 0).
Statistical analyses
All statistical analyses were performed using R v 3.1.2 (R
Core Team 2014) and we defined a significance threshold
of P = 0.05 for all tests. A more detailed description of the
rationale for the statistical approaches used is provided in
the Supporting information. The doses required to cause
40% and 80% mortality of the ancestral SP8 strain were
estimated, with 95% CI’s, using the drc package (Ritz and
Streibig 2007). In order to calculate estimates of these two
doses, we constructed a dose–response curve of the
relationship between worm survival and concentration of
Ivermectin. We fitted a range of dose–response models
(log-logistic, Weibull-1, and Weibull-2) with the lower
asymptote of the curve fixed at 0% survival and used
maximum likelihood to select the most appropriate model
of survival data. Ivermectin concentration and batch were
fitted as fixed effects in our full model. To assess whether
the relationship between survivorship and Ivermectin
concentration remained the same between batches
performed at different times (i.e. repeatability), batch was
removed from the model and compared against the full
model using a likelihood ratio test. Estimates of the
required doses, with 95% CIs, were then derived from
model predictions.
Our experimental design incorporated a power analysis,
which specifically adjusted for the effects of the number of
lines, interline variation, the potential observable difference
in survival between treatments (effect size), and bioassay
replicate (Johnson et al. 2015). We estimated that our
experimental design gave 93% power to detect an absolute
difference in survivorship of 10% in the high-dose environ-
ment between the control Z lines and both HD and HR
lines. To assess whether survivorship changed over the
course of the selection experiment, data from the resistance
bioassay were analyzed using generalized linear mixed
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models using the glmer function in the lme4 package
assuming a binomial error distribution with a logit link
function (Bates et al. 2014; see Supporting information).
Treatment and generation and the interaction between
them were fitted as fixed effects. The evolutionary replicate
(line) was fitted as a random effect. An observation-level
random effect was fitted to account for any overdispersion
between replicate lines in the selection experiment and
repeated sampling of populations in the drug resistance
bioassay (Browne et al. 2005). Treatment effects in the
selection experiment were tested using likelihood ratio
tests. The null hypothesis of no difference in survival
between the three treatments (H0: Drug = Ran-
dom = Zero) was tested independently for high- and low-
mortality selection regimes by comparing the full model
with a null model with no fixed effect of treatment or inter-
action terms. Generation was kept in the null model to
account for any drift in survivorship. Three posthoc tests
comparing treatment pairs were then conducted to assess
the effects of individual treatments. This general approach
was used to answer each of our research questions.
Results
What is the relationship between Caenorhabditis remanei
survival and Ivermectin dose over a range of
concentrations within a single generation?
Two Ivermectin doses were chosen as drug treatments for
experimental evolution (Figure S1B): (i) a high dose that
corresponded to 80% mortality in the stock strain at a con-
centration of 2.46 ng/mL Ivermectin (95% CI: 2.41, 2.50);
and (ii) a low dose that corresponded to 40% mortality at
75 h at a concentration of 1.61 ng/mL Ivermectin (95% CI:
1.55, 1.68). Analysis using comparisons of log likelihood
found that a three-parameter Weibull-1 model with the
lower asymptote fixed at zero gave the best fitting model of
survival as a function of the concentration of Ivermectin
(Figure S1A) and there was no difference between the two
survival curves for data collected in the two batches
(v2 = 6.821, df = 3, P = 0.0778; Figure S1A).
Is there an increase in survivorship of populations across
generations selected in a drug-treated environment, and
does this vary with dosage?
In the selection experiments (Fig. 2), survival in zero-dose
populations remained constant over generations; the mean
adult survival in generation 1 was 94% (CI: 90%, 99%), at
generation 5 survival was 94% (CI: 90%, 98%) and at gen-
eration 10 survival was 94% (CI: 91%, 97%). Larval off-
spring densities of zero-dose lines also remained relatively
constant over the course of 10 generations; mean larval
density at generations 0, 5, and 10 was 2079, 2051, and
1878 respectively (Figure S2). In lines treated with the
lower dose of Ivermectin, survival increased gradually over
10 generations, from 47% in generation 1 (CI: 36%, 57%)
to 73% (CI: 45%, 100%) at generation 5 and 75%
(CI: 62%, 87%) in generation 10. Larval offspring numbers
remained low in LD lines throughout the course of the
selection experiment; the mean number of offspring at gen-
eration 1 was 1088 at generations 5 and 10 it was 1132 and
1248 respectively (Figure S2). Survival in high-dose treated
populations increased more dramatically, from 30% (CI:
20%, 39%) at generation 1, to 65% (CI: 54%, 76%) at
generation 5 and 77% (CI: 49%, 100%) at generation 10.
Offspring numbers of HD lines increased during the selec-
tion experiment; the mean number of offspring was 394,
1166 and 1435 at generations 0, 5 and 10 respectively
(Figure S2).
In our formal test of changes in susceptibility of evolved
lines, challenge with the dose used during selection, HD
lines exposed to a high dose of Ivermectin for 75 h exhib-
ited an increase in mean survival of 19% and 10%, at gen-
erations 5 and 10 respectively, relative to Z lines (H0:
HD = Z: P < 0.0001; Fig. 3A, Table 1). Survival was rela-
tively consistent between lines within a treatment (Fig-
ure S3). Mean survivorship of the three HD lines remained
between 59% and 66% at both generations 5 and 10, except
in the case of one line in generation 10 where survivorship
dropped to 48%. Variation in the mean survivorship of the
six Z lines ranged between 37% and 51% at both genera-
tions 5 and 10. At 52 h of exposure to Ivermectin, the HD
lines showed a similar increase in mean survival to data col-
Figure 2 Survivorship during original selection experiments. Lines rep-
resent mean survival for each treatment; points are the proportion of
adults surviving on day 2 of each generation for each replicate line
within a treatment. Circles, solid line = zero dose; squares, dotted
line = low dose; triangles, dashed line = high dose. Error bars; standard
error for mean survival.
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lected at 75 h (Table S1, Figure S4A). Thus, both juveniles
and adults exhibited a comparable response to selection in
terms of increased survival in the high-dose environment.
LD lines exposed to a low dose of Ivermectin for 75 h
showed no increase in survival relative to control lines (H0:
LD = Z: P = 0.11; Fig. 3B, Table 1), but at the earlier
observation time of 52 h LD lines exhibited increased sur-
vival relative to Z lines at both generations 5 and 10 (H0:
LD = Z: P = 0.022; Table S1, Figure S4B). Therefore,
selection at the low dose of Ivermectin resulted in higher
survivorship of juveniles but not adults when re-exposed to
a low-drug dose.
Does density-dependent selection affect the apparent
evolution of resistance in selected lines?
In the selection experiment, survival in both random mor-
tality treated lines remained of a similar magnitude to zero-
dose lines prior to random removal of worms; the mean
adult survival of LR lines at generation 1 was 95% (CI:
92%, 98%), at generation 5 survival was 97% (CI: 86%,
100%) and at generation 10 survival was 93% (CI: 90%,
96%). Larval densities of LR lines remained similar to those
of LD lines during the selection experiment; the mean
number of larvae was 1088, 1132, and 1248 at generations
0, 5, and 10 respectively (Figure S2). Mean adult survival
of HR lines at generation 1 was 96% (CI: 91%, 100%), at
generation 5 survival was 96% (CI: 87%, 100%) and at gen-
eration 10 survival was 95% (CI: 87%, 100%). Offspring
numbers of HR lines during the selection experiment
remained lower than zero-dose controls; the mean number
of offspring was 1083, 1203, and 1172 at generations 0, 5,
and 10, respectively (Figure S2).
Surprisingly, in the resistance bioassays, high random
mortality (HR lines) showed an increase in mean survival
when populations were challenged with a high dose of Iver-
mectin. Mean survival of HR lines was 9% higher than Z
lines for both generations 5 and 10 after 75 h (H0: HR = Z:
P = 0.014; Fig. 3A, Table 1). Therefore, reducing density by
removing individuals randomly had a similar effect to drug
treatment in HD lines. However, there was a difference
between HD and HR treatments; HD lines showed higher
survival at generation 5 but not 10 (H0: HD = HR:
P = 0.038; Fig. 3A, Table 1). Variation in mean survivor-
ship of the three HR lines remained consistently between
50% and 56% at both generations 5 and 10; smaller than
the between-line variation observed in both HD and Z lines
(Figure S3). At 52 h of drug exposure, the increase in sur-
vival of HR lines relative to Z lines was comparable to that
of data collected at 75 h (Table S1, Figure S4A). Thus,
when exposed to the high dose of Ivermectin, survival of
both juveniles and adults from HR lines responded to selec-
tion in a similar manner. Survivorship of lines selected in
the LR environment showed no response to selection when
exposed to a low dose of Ivermectin for 75 h; survivorship
remained comparable to that of Z lines at both generations
5 and 10 (H0: LD = LR = Z: P = 0.11; Fig. 3D, Table 1).
However, when survival of LD lines was observed at 52 h
of exposure to a low-drug dose, survival was similar to LD
lines, relative to Z lines (H0: LR = Z: P = 0.035; Fig-
ure S4A, Table S1). As was the case with LD lines,
increased survivorship of LR lines in the low-dose environ-
ment was only observed for juveniles at 52 h, and not
adults at 75 h.
Is there a cost of adaptation to drug-treated environments
in terms of survival in drug-free environments?
In an environment where no drug was administered, HD
and HR lines performed equally as well as Z lines in terms
of survival over 75 h (H0: v
2 = 3.95, df = 2, P = 0.47;
Fig. 3C, Table 1). In contrast, LD lines had significantly
lower survivorship than Z lines in the drug-free environ-
ment. However, this was only apparent at generation 10
and the magnitude of the effect was relatively small (H0:
Figure 3 Seventy-five hour survival when exposed to the three drug
doses used during selection (A = high; B = low: C and D = zero) of
samples taken from generations 0, 5, and 10 during selection. (A, C)
Survivorship of high mortality lines: HD and HR. (B, D) Survivorship of
low-mortality lines: LD and LR. Points are mean survival data for each
replicate population, lines represent predictions of maximal models
(generation + treatment + generation*treatment) for each treatment:
circles, solid line = zero dose; triangles, dashed line = drug treatment;
diamonds, dotted line = random mortality. Error bars; 95% confidence
intervals for mean survival. HR, high random; LR, low random.
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LD = Z: P = 0.0035; Fig. 3D, Table 1). LR lines also
maintained a similar response in survivorship as Z lines at
both generation 5 and 10 (H0: LR = Z: P = 0.40; Fig. 3D,
Table 1), and there was no significant difference between
LR and LD lines with respect to survival (H0: LD = LR:
P = 0.20; Fig. 3D, Table 1). The relationship in survival
measurements taken at 52 h for the evolved lines remained
similar to survival measured at 75 h for all treatments
(Table S1, Figure S4C,D).
Does survival of different life-history stages (juvenile and
adult) respond to drug-selection in the same way?
Mortality due to drug challenge continued between 52 and
75 h in HD and LD selected lines when challenged with
Ivermectin and was of a greater magnitude than observed
in a drug-free environment (Fig. 3 and Figure S4). When
exposed to the dose used during selection, HD lines
showed no interaction between generation and selection
regime at 52 h (v2 = 1.33, df = 2, P = 0.51) but at 75 h an
interaction was apparent (v2 = 5.96, df = 2; P = 0.05). The
change in significance of treatment and generation interac-
tions indicates a change in the way juvenile and adult sur-
vival responded to drug selection in HD lines; juvenile
survival remained similar between generations 5 and 10,
whilst adult survival declined (Fig. 3A and Figure S4A).
When worms were exposed to a low dose of Ivermectin, we
observed differential survival between LD and control (Z)
lines at 52 h but not at 75 h (Fig. 3B and Figure S4B,
Table 1); suggesting that juvenile survival responded to
drug selection but adult survival remained unaffected by
drug treatment.
In our pooled data sets, we found no evidence of a three-
way interaction between selection experiment treatment,
bioassay dose and life-history stage at generations 5 or 10
(v2 = 2.77, df = 4, P = 0.60, v2 = 0.47, df = 4, P = 0.98,
respectively). However, there was a significant two-way
interaction between selection experiment treatment and
bioassay dose at both generations 5 and 10 (v2 = 28.98,
df = 4, P < 0.0001, v2 = 38.96, df = 4, P < 0.0001, respec-
tively); suggesting that survival in drug-treated environ-
ments was dependent on selection regime. In addition,
there was an interaction between bioassay dose and life-his-
tory stage at generation 5 but not generation 10 (v2 = 6.07,
df = 2, P = 0.048, v2 = 3.82, df = 2, P = 0.15, respec-
tively). There was no evidence of an interaction between
selection experiment treatment and life-history stage for
generations 5 or 10 (v2 = 0.77, df = 2, P = 0.68, v2 = 4.40,
df = 2, P = 0.11, respectively).
Discussion
What is the relationship between Caenorhabditis remanei
survival and Ivermectin dose over a range of
concentrations within a single generation?
The dose–response curve of the survival of the drug-naive
ancestral strain of C. remanei (SP8) was similar to those
previously reported for drug-naive C. elegans when chal-
lenged with a range of Ivermectin concentrations (James
and Davey 2009). The confidence intervals of the two Iver-
mectin doses used in the selection experiment differed; the
high dose had narrower intervals than the low dose. This
suggests that the intensity of selection applied to the first
generation of the selection experiment was more variable in
lines exposed to low doses of Ivermectin, though even at
low doses this would translate into no more than 3.25%
variation in survival.
Table 1. Effect of treatment during selection (mortality treatment) on survivorship (Surv.diff) after 75 h, in drug-treated environments (dose);
assessed by null models (see Data S1), using likelihood ratio tests, where survival is constrained to be equal across treatments, and dependent upon
the best fitting model.
Mortality treatment Dose Best fitting model Null models v2 (df) P-value
Surv.diff
Gen 5 Gen 10
High High G + T + G 9 T 1. HD = HR = Z 22.26 (4) 0.00018
2. HD = Z 21.11 (2) <0.0001 0.19 0.10
3. HR = Z 8.56 (2) 0.014 0.09 0.09
4. HD = HR 6.56 (2) 0.038 0.10 0.01
Zero G 1. HD = HR = Z 3.59 (2) 0.47
Low Low G 1. LD = LR = Z 7.67 (2) 0.11
Zero G + T + G 9 T 1. LD = LR = Z 11.47 (4) 0.022
2. LD = Z 11.33 (2) 0.0035 0.01 0.06
3. LR = Z 1.84 (2) 0.40 0.00 0.02
4. LD = LR 3.25 (2) 0.20 0.01 0.04
G, generation; T, treatment; G 9 T, generation 9 treatment interaction; HD, high-dose treatment; HR, high random treatment; LD, low-dose treat-
ment; LR, low random treatment; Z, zero-dose treatment; df, degrees of freedom; Surv.diff: absolute difference in mean survival between the high-
lighted treatments (first minus second).
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Do drug-treated lines show an increase in survivorship
across generations in drug-treated environments, and does
this vary with dose?
Census data from the selection experiment indicated that
populations of C. remanei exposed to low and high doses
of Ivermectin showed a response to selection in terms of
increased survival over 10 generations (Fig. 2, Table 1).
Furthermore, the increase in survivorship in HD lines was
of a greater magnitude than LD lines, suggesting that evo-
lution was more rapid in populations exposed to a higher
drug dose. The data from resistance bioassays support the
responses observed in the selection experiment in terms of
the greater magnitude of response in survivorship of HD
lines relative to LD lines. In both dosage regimes, the
increase in survivorship during the selection experiment
slowed over the course of the experiment, suggesting a
rapid response of populations to drug treatment that
reached a peak for a given drug dose. Rapid responses to
drug selection and peaking of the response have been previ-
ously observed in Levamisole-selected strains of C. elegans
(Lopes et al. 2008).
Previous research focused on under-dosing has suggested
that lower doses (doses below recommended use) may pro-
mote the evolution of resistance, especially where the basis
of resistance is polygenic (Manalil et al. 2011; Shi et al.
2013), and that varying the level of under-dosing may affect
the rate at which resistance evolves (Busi and Powles 2009).
Our data suggest that selection at a low dose of Ivermectin
conferred no advantage on LD lines when re-exposed to
the low-dose environment for 75 h. However, HD-selected
lines showed higher survivorship relative to Z lines on
exposure to the high-drug dose. Thus, the intensity of
selection played a role in how selected populations
responded to Ivermectin treatment. The lack of a response
in survival of LD lines exposed to the low dose for 75 h
conforms to models of resistance evolution in nematodes
where under-dosing retards the development of resistance
(Barnes et al. 1995). Under such models under-dosing may
reduce the evolution of resistance by allowing more suscep-
tible worms to survive.
Does density-dependent selection affect the apparent
evolution of resistance in selected lines?
Intriguingly, survival of lines selected in random-mortality
environments showed a similar trend, but of a lower mag-
nitude, to drug-selected lines, and in contrast to zero-dose
lines, suggesting that density-dependent effects on life-his-
tory traits might be affecting the apparent rate of resistance
evolution. Random culling of adults reduced larval densi-
ties in random mortality treated lines; meaning that larval
densities remained comparable to drug-treated lines and
lower than control (Z) lines. Density-dependent natural
selection has been shown to affect the competitive abilities
of selected lines; Mueller (Mueller 1988) showed that the
feeding efficiency of K-selected (high density) lines was
58% greater than r-selected (low density) lines of Droso-
phila melanogaster after 128 generations of density-depen-
dent selection. Though our selection experiment design
aimed to provide an abundant bacterial food source, at the
time lines were transferred to new plates, bacterial lawns
were patchy and no doubt some competition for resources
is likely to have occurred. Life-history traits such as devel-
opment time, size at maturity and reproduction may all be
influenced by density-dependent selection (Joshi et al.
2001; Prasad and Joshi 2003; Dey et al. 2012). If traits asso-
ciated with selection in a low-density environment confer
an advantage in a novel drug-treated environment, then
this may explain the observed increase in survivorship of
random-mortality lines relative to control (Z) lines. Thus,
much of the observed response in survivorship in drug-
treated and random-mortality lines when challenged with
Ivermectin could be due to increased tolerance as a result
of density-dependent processes, rather than resistance evo-
lution per se. Put another way, if the response in survival of
HR lines is attributable to the evolution of tolerance then
perhaps a large part of the response in survival of HD lines,
which would have faced similar density-dependent pro-
cesses to HR lines, is also due to selection for tolerance
rather than resistance.
Alternatively, the increase in survivorship of drug-treated
and random-mortality lines when exposed to drug treat-
ment could be a result of loss of genetic variation due to
drift. This hypothesis would require all lines to drift in the
same direction, which could have occurred during bottle-
necking of drug-treated and random-mortality lines, par-
ticularly in the early generations of selection. However, the
loss of diversity may not have been severe relative to the
control zero-dose lines (see Data S1: drift and loss of diver-
sity). Our theoretical predictions of the loss of genetic
diversity in HR and Z lines suggest that both treatments
went through similar losses of genetic diversity. Predicted
heterozygosity and the total number of alleles decreased
more rapidly in HR lines relative to Z lines but the differ-
ence between the two treatments was small. In the case of
rare alleles, it is likely that any rare allele would have been
lost from populations in both HR and Z lines. Thus, it
seems likely that any evolved increase in survivorship of
HR and potentially drug-treated lines, was due to ecologi-
cal processes occurring as a consequence of density-depen-
dent selection and not loss of genetic variation due to drift.
Differentiating between the effects of drug selection and
traits not directly associated with resistance has been a
long-standing problem in studies of resistance evolution
(Chehresa et al. 1997; Gilleard and Beech 2007). The
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increase in survival of HR lines over generations when chal-
lenged with both low and high drug doses was of a lower
magnitude than HD lines; this difference in absolute sur-
vival could represent the effects of selection solely due to
drug treatment. If this is the case, then our experimental
design provides a means of partitioning the evolved
response in survival due to drug application and responses
due to the effects of population size, density, and the risk of
mortality. Increased parasite densities generally have a neg-
ative effect on traits such as survival and fecundity
(Churcher et al. 2006); however, how density-dependence
interacts with drug treatment remains unclear and may
depend upon which life-history stage is most severely
affected by the drug (Churcher and Basa~nez 2008). It is also
possible that the difference in survivorship between HR
and HD lines was due to the experimental protocol during
selection. Random-mortality populations were culled once
every 24 h to simulate the same level of mortality as ‘sister’
drug-treated populations, but drug-treated populations are
likely to have suffered additional mortality over the course
of this 24-h period. This would have resulted in a lag
between drug-induced mortality and culling between ‘sis-
ter’ populations. If HR lines had tracked the rate of mortal-
ity in HD lines more closely, maintaining similar densities
between HD and HR treatments, potentially the same mag-
nitude of response could have been observed in both high
mortality treatments, regardless of mortality source. A
more synchronized method of tracking drug-dependent
mortality and imposing compensatory mortality on ran-
dom-mortality lines would reveal whether the lag in ran-
dom culling is responsible for the difference in
survivorship between HR and HD lines.
Is there a cost of adaptation in drug-treated environments
in terms of survival in drug-free environments?
When random-mortality and drug-treated lines were
exposed to a drug-free environment, no differences were
observed in survivorship relative to Z lines. Therefore, bot-
tlenecking and small population size of random-mortality
lines resulted in no beneficial or detrimental effects on sur-
vival in an environment where no extrinsic mortality was
imposed. It has been suggested that the evolution of
reduced susceptibility may lead to fitness costs in life-his-
tory traits if resistance is costly (Roush and McKenzie
1987). In order to assess the fitness costs that might result
from reduced susceptibility one could either measure gene
frequencies of susceptible alleles over a number of genera-
tions in the absence of the drug (Roush and McKenzie
1987) or estimate fitness based on measures of life-history
traits such as fecundity, development time, fertility and
mating competitiveness (Carriere et al. 1994; Gassmann
et al. 2009) in the presence and absence of the drug. In this
study, we looked solely at differences in survival in drug-
free and drug-treated environments; it would be interesting
to assess a suite of traits associated with fitness and explore
their relationship with apparent susceptibility to Iver-
mectin.
Do different life-history stages respond to drug selection
in the same way?
Mathematical models have suggested that the life history of
parasites may evolve in response to drug-treatment as a
result of altering parasite survival and reproduction (Lynch
et al. 2008). The differing responses of life-history stage
(juveniles and adults) in HD and LD lines at low and high
dosages suggest that age-related effects and interactions
with selection intensity may be important to consider in
predicting resistance or tolerance evolution. We observed a
significant interaction between resistance bioassay dose and
life history. In addition, resistance bioassay data from 75 h
showed a response in survivorship of HD lines but not LD
lines; i.e. adults of HD lines were less susceptible than Z
lines whereas LD lines remained of a similar susceptibility
to Z lines, across selected generations. However, 52-h
bioassay data showed that both HD and LD lines
responded to drug selection in terms of increased survivor-
ship. Therefore, at the high dose of Ivermectin, both juve-
niles and adults responded to drug selection, whereas at
low doses only juveniles responded to selection.
Body size is often used as a predictor of fecundity across
a range of nematode species (Morand 1996). Under stan-
dard life-history theory, interventions that reduce adult life
expectancy should select for parasites that mature earlier at
a reduced size and produce fewer offspring (Roff 1992;
Stearns 1992; Skorping and Read 1998). However, Lynch
et al. (2008) used mathematical models to demonstrate
that interventions that affect mortality rates of mature par-
asitic nematodes could have complicated effects on optimal
age to maturity, regardless of whether mortality is size-
dependent or independent. They argued that where an
intervention measure is continuously applied, the optimum
age at maturity may be longer relative to a situation with
no intervention and that parasites should benefit from a
greater reproductive life span. Field experiments studying
the evolutionary effects of anthelmintics on Teladorsagia
circumcincta showed that worm size was consistently larger
in resistant isolates when compared to susceptible isolates
(Leignel and Cabaret 2001). Worryingly, if drug selection
favors increased size at maturity then resistant worms may
be more fecund than susceptibles. It would be interesting
to measure size at maturity as well as other life-history
traits of our evolved lines and investigate whether any
responses in such traits correlate with apparently reduced
susceptibility to Ivermectin.
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Conclusions
Our inclusion of a novel treatment that controls for
both the increased risk of mortality and changes in
population size of drug-treated populations raises the
question of whether previous studies that have not
incorporated such controls should be re-evaluated. For
example, Lopes et al. (2008) report the rapid evolution
of resistance to Levamisole within 10 generations of
exposure under very similar experimental conditions
to this study. Levamisole was administered at a concen-
tration lethal for 75% of the ancestral population.
A resistance bioassay was then performed on samples
from generations 10 and 20, which showed a 25%
increase in survival of populations under drug selec-
tion at generations 10 and 20. However, as there was
no control for mortality between drug-treated and con-
trol populations, it is difficult to assess whether
there were effects of differences in density and mortal-
ity between treatments. We recommend that future
work on resistance should incorporate adequate controls
for parasite/pest density when assessing drug resistance
evolution. In addition, controlling for differences in
population size and rate of mortality could be imple-
mented in any experimental evolution study where the
selective agent induces greater mortality than control
treatments.
Standing genetic variation in the form of susceptibility
to chemical applications is important in the study of
resistance evolution (Gilleard and Beech 2007). This study
suggests there may be a complex relationship between the
intensity of selection and, density-dependent regulatory
processes and life history of populations challenged with
control measures. How these factors interact and affect
characteristics such as tolerance and resistance could
result in significant impacts on the evolution of suscepti-
bility. For instance, studies of drug susceptibility in nema-
todes have shown that environments where conditions are
inhospitable to free-living larvae, which reduces larval
densities, promote the evolution of resistance (Besier and
Love 2003; Lawrence et al. 2007; Leathwick and Besier
2014). What proportion of this reported resistance is due
to drug application or tolerance, and how it interacts with
life history, is difficult to establish in the field. In order to
understand how drug tolerance and resistance evolution
may interact, future research should aim to identify pre-
cisely which traits are associated with tolerance and what
influence they may have on resistance. The Caenorhabditis
system allows a range of traits to be assessed over the
course of selection experiments (Gray and Cutter 2014),
and therefore should provide an invaluable model to
explore factors which may affect the evolution of resis-
tance and tolerance.
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Supporting Information
Additional Supporting Information may be found online in the support-
ing information tab for this article:
Figure S1. Relationship between survival and dose of Ivermectin for
the SP8 strain of Caenorhabditis remanei.
Figure S2. Larval density over the course of the original selection
experiment.
Figure S3. Seventy-five hour survival of high dose, high random and
zero dose lines when exposed to the high dose of Ivermectin used during
selection.
Figure S4. Fifty-two hour survival when exposed to the three drug
doses used during selection (A = high; B = low: C and D = zero) of
samples taken from generations 0, 5 and 10 during selection.
Table S1. Effect of treatment during selection (mortality treatment)
on survivorship (Surv.diff) at two different time points (Bioassay), in
drug-treated environments (dose); assessed by null models where sur-
vival is constrained to be equal across treatments (see Data S1), using
likelihood ratio tests of best the fitting model.
Table S2. Predicted theoretical loss of genetic diversity based on a
simple population genetic model during the course of selection (genera-
tion) in HR (high random) and Z (zero dose) lines.
Data S1. Example R code for bioassay data analysis.
Data S2. Supplementary material: statistical methods and drift and
loss of diversity.
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